Genetic polymorphisms of pharmacogenomic VIP variants in the Dai population from Yunnan province

Abstract

BackgroundPharmacogenomics plays a crucial role in individualized therapy, but the variant information of pharmacogenomics in the Dai population is limited. We therefore aimed to screen very important pharmacogenetic (VIP) in the Dai population and compared differences between Dai and other 25 populations.MethodsIn this study, we genotyped 73 VIP variants from the PharmGKB and compared genotype distribution of variants in Dai with other 25 populations by χ2 test. To assess the genetic relationship among 26 populations, we performed the structure analysis. In addition, pair‐wise F‐statistics (Fst) was calculated to measure the population differentiation.ResultsWe found 12, 10, 13, 17, 11, 39, 46, 46, 45, 43, 49, 46, 46, 46, 49, 45, 41, 42, 48, 53, 45, 50, 50, 51, 47, and 50 significantly different variants in Dai compared with other 25 populations. Genetic structure analysis showed Dai had close relationships with CDX (Chinese Dai in Xishuangbanna), CHB (Han Chinese in Beijing), JPT (Japanese in Tokyo), and KHV (Kinh in Ho Chi Minh City, Vietnam). Moreover, Dai is the most similar to KHV according to Fst analysis.ConclusionsOur study complement the pharmacogenomics information of Dai population from Yunnan province and provide a theoretical basis for personalized medicine.

Population Genetic Difference of Pharmacogenomic VIP Variants in the Tibetan Population

“…They assessed the relationship between the VIP variants and specific drugs, and provide individuals with appropriate drugs at proper doses. 6 …”

“…They assessed the relationship between the VIP variants and specific drugs, and provide individuals with appropriate drugs at proper doses. 6 There are many differences in genetic heterogeneity and genetic polymorphism among different ethnic groups. 7 An important research hotspot in pharmacogenomics is to compare the efficacy of drugs among different races.…”